Finding new ways to stop tau protein from causing Alzheimer's disease
Preventing Tau uptake by novel inhibitors of tau binding to LRP1
This study is looking at how a protein called tau spreads in the brain and causes Alzheimer's disease, and it's exploring a way to stop this process by finding small molecules that can block tau from connecting to a specific receptor, which could help create new treatments for people with Alzheimer's.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Santa Barbara NIH-funded |
| Lab location | 1 site (Santa Barbara, United States) |
| Project ID | NIH-10983793 on NIH RePORTER |
What this research studies
This research focuses on understanding how the tau protein spreads in the brain and contributes to Alzheimer's disease. The team is investigating a specific receptor, LRP1, that tau binds to, which may play a crucial role in the progression of the disease. By identifying small molecules that can prevent tau from binding to LRP1, the researchers aim to develop new treatments that could halt or slow down the spread of tau aggregates. This innovative approach could lead to breakthroughs in managing Alzheimer's disease and improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it due to genetic or environmental factors.
Not a fit: Patients with other forms of dementia unrelated to tau pathology may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively prevent or slow the progression of Alzheimer's disease.
How similar studies have performed: While targeting tau pathology is a well-explored area, this specific approach of inhibiting tau-LRP1 interaction is novel and has not been extensively tested in clinical settings.
Where this research is happening
Santa Barbara, United States
- University of California Santa Barbara — Santa Barbara, United States (Active)
Researchers
- Principal investigator: Kosik, Kenneth Stephen — University of California Santa Barbara
- Study coordinator: Kosik, Kenneth Stephen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.